ESMO Immuno-Oncology 2022 | What does the future hold for cellular therapies in solid tumors?

Michael Nishimura, PhD, Loyola University Chicago, Chicago, IL, comments on strategies to further enhance the usage of CAR-T cells in solid tumors. Current research on neoantigen-based CAR-T cells may improve efficacy in a hostile tumor microenvironment. Reducing immunogenicity will additionally reduce neurotoxicity and adverse events such as cytokine release syndrome (CRS), especially in anti-CD19 CAR-T cells. This interview took place at the ESMO Immuno-Oncology Congress 2022 in Geneva, Switzerland.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.